{"type": "root", "children": [{"type": "p", "children": [{"type": "t", "text": "\nRecent studies indicate that long noncoding RNAs (lncRNAs) are key regulators in hepatocellular carcinoma (HCC) by functioning as competing endogenous RNAs that modulate microRNA availability. In one study, an lncRNA—characterized as CACNA1G‐AS1—was found to be significantly upregulated in HCC tissues relative to adjacent normal samples. This upregulation correlated with poorer patient prognoses and enhanced tumor cell proliferation, migration, and invasion. Notably, the lncRNA exerts its action by “sponging” microRNA‐2392, thereby relieving its inhibitory effect on downstream targets."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "1"}]}, {"type": "t", "text": "\n"}]}, {"type": "t", "text": "\n\n"}, {"type": "p", "children": [{"type": "t", "text": "\nA complementary study focused on C1orf61, a transcriptional activator whose expression is augmented during key developmental phases and re‐activated in HCC. C1orf61 was shown to drive processes essential for tumor initiation and progression, including epithelial–mesenchymal transition (EMT), by upregulating genes related to cell growth, migration, and invasion. Furthermore, C1orf61 appears to influence oncogenic signaling via the STAT3 and Akt pathways and even enhances the clinical efficacy of sorafenib in HCC therapy."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "2"}]}, {"type": "t", "text": ""}]}, {"type": "t", "text": "\n\n"}, {"type": "p", "children": [{"type": "t", "text": "\nAlthough the provided abstracts do not explicitly mention MIR9‑1HG, its function in HCC can be inferred from these findings. MIR9‑1HG—akin in regulatory logic to CACNA1G‑AS1—may similarly operate as a ceRNA that sequesters specific microRNAs to derepress oncogenic targets like C1orf61. Through this microRNA/C1orf61 axis, MIR9‑1HG would promote malignant phenotypes including EMT, enhanced cellular proliferation, and metastasis, thereby making it a potential candidate for targeted therapeutic intervention."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "1"}]}, {"type": "t", "text": ""}]}, {"type": "rg", "children": [{"type": "r", "ref": 1, "children": [{"type": "t", "text": "Jinghui Yang, Chunsheng Li, Hang Li, et al. "}, {"type": "b", "children": [{"type": "t", "text": "LncRNA CACNA1G-AS1 facilitates hepatocellular carcinoma progression through the miR-2392/C1orf61 pathway."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "J Cell Physiol (2019)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1002/jcp.28477"}], "href": "https://doi.org/10.1002/jcp.28477"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "30908634"}], "href": "https://pubmed.ncbi.nlm.nih.gov/30908634"}]}, {"type": "r", "ref": 2, "children": [{"type": "t", "text": "You Yu, Zhimeng Wang, Zan Huang, et al. "}, {"type": "b", "children": [{"type": "t", "text": "C1orf61 promotes hepatocellular carcinoma metastasis and increases the therapeutic response to sorafenib."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Biochim Biophys Acta Mol Cell Res (2021)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1016/j.bbamcr.2021.119048"}], "href": "https://doi.org/10.1016/j.bbamcr.2021.119048"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "33915231"}], "href": "https://pubmed.ncbi.nlm.nih.gov/33915231"}]}]}]}